A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors
Public ClinicalTrials.gov record NCT02501096. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label Phase 1b/2 trial of lenvatinib (E7080) plus pembrolizumab in participants with selected solid tumors. Phase 1b will determine and confirm the maximum tolerated dose (MTD) for lenvatinib in combination with 200 milligrams (mg) (intravenous \[IV\], every 3 weeks \[Q3W\]) pembrolizumab in participants with selected solid tumors (i.e. non-small cell lung cancer, renal cell carcinoma, endometrial carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, melanoma or leiomyosarcoma). Phase 2 (Expansion) will evaluate the safety and efficacy of the combination in 7 cohorts at the MTD from Phase 1b (lenvatinib 20 mg/day orally + pembrolizumab 200 mg Q3W, IV).
Study identification
- NCT ID
- NCT02501096
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 357 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 21, 2015
- Primary completion
- Aug 17, 2020
- Completion
- Jul 10, 2022
- Last update posted
- Jul 19, 2023
2015 – 2022
United States locations
- U.S. sites
- 50
- U.S. states
- 13
- U.S. cities
- 37
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alaska Clinical Research Center | Anchorage | Alaska | — | — |
| Arizona Oncology Associates | Oro Valley | Arizona | — | — |
| Arizona Oncology Associates, PC - HOPE, Site #1 | Tucson | Arizona | — | — |
| Arizona Oncology Associates, PC - HOPE, Site #2 | Tucson | Arizona | — | — |
| Arizona Oncology Associates, PC - HOPE, Site #3 | Tucson | Arizona | — | — |
| Rocky Mountain Cancer Centers | Aurora | Colorado | — | — |
| Rocky Mountain Cancer Centers | Boulder | Colorado | — | — |
| Rocky Mountain Cancer Centers | Colorado Springs | Colorado | — | — |
| Rocky Mountain Cancer Centers, Site #1 | Denver | Colorado | — | — |
| Rocky Mountain Cancer Centers, Site #2 | Denver | Colorado | — | — |
| Rocky Mountain Cancer Centers | Lakewood | Colorado | — | — |
| Rocky Mountain Cancer Centers | Littleton | Colorado | — | — |
| Rocky Mountain Cancer Centers | Lone Tree | Colorado | — | — |
| Rocky Mountain Cancer Centers | Longmont | Colorado | — | — |
| Rocky Mountain Cancer Centers | Parker | Colorado | — | — |
| Rocky Mountain Cancer Centers | Pueblo | Colorado | — | — |
| Rocky Mountain Cancer Centers | Thornton | Colorado | — | — |
| Baptist Health Medical Group Oncology, LLC, Site #1 | Miami | Florida | — | — |
| Baptist Health Medical Group Oncology, LLC, Site #2 | Miami | Florida | — | — |
| Baptist Health Medical Group Oncology, LLC, Site #3 | Miami | Florida | — | — |
| Boca Raton Clinical Research Medical Center | Plantation | Florida | — | — |
| Piedmont Cancer Institue | Atlanta | Georgia | — | — |
| The University of Chicago | Chicago | Illinois | — | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | — | — |
| Mass General Hospital | Boston | Massachusetts | — | — |
| University of Minnesota, Masonic Cancer Center | Minneapolis | Minnesota | — | — |
| Comprehensive Cancer Centers of Nevada, Site #1 | Henderson | Nevada | — | — |
| Comprehensive Cancer Centers of Nevada, Site #2 | Henderson | Nevada | — | — |
| Comprehensive Cancer Centers of Nevada, Site #3 | Henderson | Nevada | — | — |
| Comprehensive Cancer Centers of Nevada, Site #1 | Las Vegas | Nevada | — | — |
| Comprehensive Cancer Centers of Nevada, Site #2 | Las Vegas | Nevada | — | — |
| Comprehensive Cancer Centers of Nevada, Site #3 | Las Vegas | Nevada | — | — |
| Comprehensive Cancer Centers of Nevada, Site #4 | Las Vegas | Nevada | — | — |
| New York Hematology Oncology (US Onc) | Albany | New York | — | — |
| Memorial Sloan Kettering at Westchester | Harrison | New York | — | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | — | — |
| Oregon Health & Science University | Portland | Oregon | — | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | — | — |
| Texas Oncology-Bedford | Bedford | Texas | — | — |
| Texas Oncology (US Onc) | Dallas | Texas | — | — |
| Texas Oncology | Dallas | Texas | — | — |
| Texas Oncology-Denton South | Denton | Texas | — | — |
| Texas Oncology-Fort Worth, Site #1 | Fort Worth | Texas | — | — |
| Texas Oncology-Grapevine | Grapevine | Texas | — | — |
| Texas Oncology-Longview Cancer Center | Longview | Texas | — | — |
| Texas Oncology-Plano West | Plano | Texas | — | — |
| South Texas Accelerated Research Therapeutics, LLC | San Antonio | Texas | — | — |
| Texas Oncology-Tyler | Tyler | Texas | — | — |
| Texas Oncology-Waco, Site #1 | Waco | Texas | — | — |
| Texas Oncology-Waco, Site #2 | Waco | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02501096, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 19, 2023 · Synced Sep 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02501096 live on ClinicalTrials.gov.